Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients with Type 2 Diabetes Mellitus uncontrolled on oral antihyperglycemic drugs

Trial Identifier:	LPS16665
Sponsor:	sanofi
Start Date:	June 2021
Primary Completion Date:	December 2022
Study Completion Date:	December 2022
Condition:	Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
India	Jaipur, India, 302017
India	Nasik, India, 422002

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.